Paytm is in focus after Goldman Sachs raised its target price for One 97 Communications to ₹2,070 from ₹1,500, citing market share, revenue growth and improving margins. The brokerage also maintained its Buy rating. However, Paytm shares came under heavy selling on October 8 after reports that the UPI Merchant Discount Rate (MDR) rollout could be deferred from October 15 to January 1, 2027.
Key Points:
- Goldman Sachs raised its target price to ₹2,070 from ₹1,500.
- Brokerage said UPI MDR could drive up to 40% EBITDA upgrades for Paytm.
- Goldman raised Paytm’s EPS estimates by up to 39%.
- Paytm shares fell sharply, with the stock hitting a 10% lower circuit at ₹1,734.
- Proposed MDR is 0.4% on eligible UPI merchant transactions above ₹2,000.
- NPCI is yet to take a final decision on the possible delay.
Paytm is facing contrasting signals: positive brokerage expectations but near-term uncertainty over UPI MDR implementation.
Paytm aaj focus mein hai kyunki Goldman Sachs ne One 97 Communications yani Paytm ka target price ₹1,500 se badhakar ₹2,070 kar diya hai. Brokerage ne company ke revenue growth, market share aur improving margins ko positive factors bataya hai. Lekin isi beech UPI Merchant Discount Rate yani MDR ke implementation ko lekar uncertainty se Paytm shares par pressure dekha gaya. Reports ke according, 15 October se proposed MDR rollout ko 1 January 2027 tak defer kiya ja sakta hai.
Key Points:
- Goldman Sachs ne target ₹1,500 se ₹2,070 kiya.
- Brokerage ne Paytm par Buy rating maintain ki.
- MDR se Paytm ki earnings potential improve hone ki expectation hai.
- Goldman ne Paytm ke EPS estimates ko up to 39% raise kiya.
- Paytm shares mein 10% tak ki girawat dekhi gayi.
- Stock ₹1,734 ke lower circuit tak pahucha.
- MDR implementation delay par abhi final decision nahi hua hai.
Paytm ke liye picture mixed hai—brokerage ka outlook positive hai, lekin MDR delay near-term uncertainty create kar raha hai.